Filing Flows › Seres Therapeutics (MCRB) › Q3 2025
Seres Therapeutics (MCRB) Q3 2025 earnings results (third quarter 2025)
10-Q filed Nov 5, 2025
Seres Therapeutics (MCRB) reported revenue of $351K for the third quarter 2025 (Q3 2025).
Seres Therapeutics, Q3 2025: revenue $351K, net earnings $8.2M, operating cash flow $2.2M. The chart follows the revenue to costs, profit and cash.
| Q3 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $351K | — | — |
| Operating profit | −$22.5M | — | — |
| Net earnings | $8.2M | — | — |
| Operating cash flow | $2.2M | — | — |
| Free cash flow | $2.2M | — | — |
What changed
Revenue was $351K in Q3 2025.
Operating costs exceeded revenue by $22.5M, an operating margin of -6403.7%. Net earnings were $8.2M. The effective tax rate was 0.0%. Non-operating items added $30.7M, 374% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $2.2M, 27% of net earnings. Non-cash charges added back $1.0M of depreciation and amortization and $2.5M of share-based compensation. Working capital and other items used $9.5M. Capital expenditures of $8K left free cash flow of $2.2M.
Questions
What was Seres Therapeutics' revenue in the third quarter 2025?
Seres Therapeutics (MCRB) reported revenue of $351K for the third quarter 2025 (Q3 2025).
Source: Seres Therapeutics 10-Q on SEC EDGAR.